Abstract #4314

Detection of Early Response to Cyclophosphamide Treatment in a Myc-Driven Lymphoma Model Using Hyperpolarized 13C-Pyruvate and FDG-PET

Tiago B. Rodrigues¹,², Mikko I. Kettunen,²³, David Y. Lewis¹, Ferdia A. Gallagher¹,⁴, Eva Serrao¹,², Dmitry Soloviev¹, Kevin M. Brindle¹

¹Cambridge Research Institute, Cancer Research UK, Cambridge, United Kingdom; ²Department of Biochemistry, University of Cambridge, Cambridge, United Kingdom; ³Cambridge Research Institute, Cancer Research UK,, Cambridge, United Kingdom; ⁴Departments of Radiology and Biochemistry, University of Cambridge, Cambridge, United Kingdom

Our main goal was to assess if hyperpolarized [1-¹³C]-pyruvate MRS could detect response within 24 hours of cyclophosphamide treatment in a Myc-driven lymphoma model and to compare it with FDG. Our results showed a 70% reduction in the pyruvate-lactate flux following treatment, whereas a more modest change was seen in FDG-PET. This demonstrates the feasibility of using hyperpolarized ¹³C-pyruvate to detect early treatment response in a transgenic mouse of lymphoma, being potentially a complement of FDG-PET as a clinical tool.